AI CuratorAI-generated
Research summary · AI summary · not yet reviewedCell studyNot reportedPublished in a peer-reviewed journal
Effects of Ibrutinib on Cell Cultures of Spinal Cord Neurons and Microglia
Ibrutinib was tested on spinal cord neuron cultures, showing it induces remyelination and lowers stathmin-1 expression. It also reduced the inflammatory response in microglia-like BV2 cells, influencing miR-223 expression in extracellular vesicles.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
These findings suggest that ibrutinib could play a role in remyelination processes and modulating inflammation, which are relevant to conditions like multiple sclerosis.
What this does not prove
The study used in vitro cell models, so direct applicability to living organisms is uncertain.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-14
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Bruton's tyrosine kinase
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceNeuron myelination is accelerated by Bruton's tyrosine kinase inhibition via microglial extracellular vesicles. ↗DOI: 10.3389/fncel.2026.1864654
Supporting passages (7)
subjectsRESULTS: We demonstrated that (1) spinal cord neuron cells represent a suitable model for investigating myelination following L‑α‑lysophosphatidylcholine (LPC) treatment; (2) ibrutinib induces remyelination and reduces stathmin‑1 expression in spinal cord cultures; and (3) ibrutinib reduces the inflammatory phenotype of microglia‑like BV2 cells, thereby modulating the expression of miR‑223 in extracellular vesicles (EVs).
findingsRESULTS: We demonstrated that (1) spinal cord neuron cells represent a suitable model for investigating myelination following L‑α‑lysophosphatidylcholine (LPC) treatment; (2) ibrutinib induces remyelination and reduces stathmin‑1 expression in spinal cord cultures; and (3) ibrutinib reduces the inflammatory phenotype of microglia‑like BV2 cells, thereby modulating the expression of miR‑223 in extracellular vesicles (EVs).
biological targetsPreclinical evidence has demonstrated that Bruton's tyrosine kinase inhibitors (BTKi), such as ibrutinib, delay MS progression by acting on myeloid cells.
publication datePublication date: 2026-10-14
limitationsTitle: Neuron myelination is accelerated by Bruton's tyrosine kinase inhibition via microglial extracellular vesicles.
peer reviewedPublication types: Journal Article
human efficacyRESULTS: We demonstrated that (1) spinal cord neuron cells represent a suitable model for investigating myelination following L‑α‑lysophosphatidylcholine (LPC) treatment; (2) ibrutinib induces remyelination and reduces stathmin‑1 expression in spinal cord cultures; and (3) ibrutinib reduces the inflammatory phenotype of microglia‑like BV2 cells, thereby modulating the expression of miR‑223 in extracellular vesicles (EVs).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.